Glen Iris, Australia

Adrian Sulistio

This inventor holds 10 USPTO granted patents, plus 3 CIPO patents and 2 EPO patents. Top assignee: Polyactiva Pty Ltd. Active years: 2017-2026.


% Patents Active = 100.0

 

 

Average Co-Inventor Count = 7.8

ph-index = 3

Forward Citations = 24(Granted Patents)


Company Filing History:


Years Active: 2017-2026

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Innovations of Adrian Sulistio

Introduction

Adrian Sulistio is a prominent inventor based in Glen Iris, Australia. He has made significant contributions to the field of drug delivery systems, holding a total of 8 patents. His work focuses on developing biodegradable drug-polymer conjugates that enhance the efficacy of drug delivery.

Latest Patents

One of his latest patents is a biodegradable drug-polymer conjugate. This innovative conjugate is a copolymer that includes a variety of functional groups and linking moieties. The design allows for the release of drugs such as prostaglandins and β-blockers, providing a versatile platform for therapeutic applications. Another notable patent is a polymer-prostaglandin conjugate, which features a polymer backbone with triazole moieties, enhancing the stability and delivery of the drug.

Career Highlights

Adrian Sulistio is currently associated with Polyactiva Pty Ltd, where he continues to push the boundaries of drug delivery technology. His work has garnered attention for its potential to improve patient outcomes through innovative drug formulations.

Collaborations

Adrian collaborates with talented individuals such as Sarah Man Yee Ng and Andrew Craig Donohue, contributing to a dynamic research environment that fosters innovation.

Conclusion

Adrian Sulistio's contributions to the field of drug delivery through his patents and collaborations highlight his role as a leading inventor in the industry. His work continues to pave the way for advancements in medical technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…